Global Cardiovascular Disease Drugs Market Forecast - Ken Research

1
Global Cardiovascular Disease Drugs Market to
2023 Ken Research
2
Global Cardiovascular Disease Drugs Market to
2023-Expiries, Acquisitions and New Products for
Deep Vein Thrombosis, Pulmonary Arterial
Hypertension and Dyslipidemia to Shake-Up the
Competitive Landscape The Cardiovascular Disease
(CVD) therapy area encompasses a range of
different diseases and conditions affecting the
heart and/or blood vessels. The most crucial risk
factors for CVD are hypertension and
dyslipidemia, which accelerate the development of
atherosclerotic plaque buildup within blood
vessels. As atheroma develops it causes the
affected blood vessels to narrow, restricting
blood flow to the body, brain or heart, depending
on its locale. It is also possible for the
fibrous cap of this plaque to break off,
triggering the coagulation cascade and causing a
thrombus to form locally, which can completely
occlude blood flow.
3
The treatments of CVD typically focus on
prevention by controlling risk factors. As such,
the treatments usually fall within three
categories Anti- hypertensives, which aim to
maintain blood pressure within a normal range
anti- dyslipidemic drugs, which aim to modify
lipid levels to a normal range and
anti-thrombotic drugs, which aim to prevent
thrombi formation by inhibiting the coagulation
cascade or platelet aggregation. There has been
vast scientific innovation in the CVD
therapeutics market in recent decades,
particularly within the anti-dyslipidemia market.
This was seen first with the introduction of
statins such as Lipitor (atorvastatin), and more
recently with the introduction of protein
convertase subtilisin/ kexin type 9 (PCSK9)
inhibitors. However, other areas such as the
heart failure market remain poorly treated.
Dyslipidemia and hypertension have continuing
high levels of development within the current
pipeline and, despite high levels of generic
development, there is also a large degree of
innovation, with targets such as apolipoproteins
and elements of the reverse lipid transport
pathway. In addition, the current pipeline
includes nearly 200 products for the treatment of
heart failure, suggesting an increase in interest
in treating the disease.
4
With over 1,400 products in active development,
the pipeline for CVD is extensive. Does current
pipeline innovation hold the potential to change
the CVD market in the near future? The clinical
trials process for CVD drugs is complex. What is
the risk of a CVD drug failing to reach the
market? What is the risk of a drug failing at a
specific Phase? The CVD market landscape is
forecast to undergo a period of substantial
change following key approvals, patent expiries
and acquisitions. Which of the leading
companies will have the highest market share by
2023? What strategies have these companies
adopted to achieve market growth? There has been
a moderately high level of deal activity in
recent years. How do deal frequency and value
compare between target families and molecule
types?
5
Key topics covered in this topic Global
Cardiovascular Disease Drugs Market Global
Cardiovascular Disease Drugs Market
Outlook Global Cardiovascular Disease Drugs
Market Value Global Cardiovascular Disease Drugs
Market Competition Analysis Global Cardiovascular
Disease Drugs Industry Growth Analysis Global
Cardiovascular Disease Drugs Market Size Global
Cardiovascular Disease Treatment Heart Disease
Treatment in Global Global Cardiovascular Disease
Drugs Market Forecast Global Cardiovascular
Disease Drugs Market Revenue Global
Cardiovascular Disease Drugs Market Share Global
Cardiovascular Disease Drugs Market SWOT
Analysis Global Cardiovascular Disease Drugs
Market Demand Global Heart Disease Medical
Treatment
6
To know more, click on the link
below https//www.kenresearch.com/healthcare/phar
maceuticals/global-cardiovascular-disease-drugs-ma
rket-to-2023/142623-91.html Contact Us Ken
Research Ankur Gupta, Head Marketing
Communications sales_at_kenresearch.com 91-901537824
9